vs
Side-by-side financial comparison of Omada Health, Inc. (OMDA) and Strata Critical Medical, Inc. (SRTA). Click either name above to swap in a different company.
Omada Health, Inc. is the larger business by last-quarter revenue ($68.0M vs $22.7M, roughly 3.0× Strata Critical Medical, Inc.). Omada Health, Inc. produced more free cash flow last quarter ($9.6M vs $-10.2M).
Omada Health, Inc. is a leading US-based digital chronic care management company. It offers evidence-based, personalized care programs for conditions including type 2 diabetes, hypertension, musculoskeletal disorders and mental health concerns, serving employers, health plans and health system clients across the United States, paired with professional coaching and digital tracking tools to support sustained member health improvements.
Strata Critical Medical, Inc. is a medical technology firm designing, producing and distributing disposable medical products for critical care, anesthesia and surgical use cases. It serves healthcare providers across North America and some European markets, focusing on improving patient safety and clinical efficiency.
OMDA vs SRTA — Head-to-Head
Income Statement — Q3 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $68.0M | $22.7M |
| Net Profit | $-3.2M | — |
| Gross Margin | 66.3% | -0.9% |
| Operating Margin | -3.7% | -18.4% |
| Net Margin | -4.7% | — |
| Revenue YoY | — | 361.2% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.06 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $22.7M | ||
| Q3 25 | $68.0M | $49.3M | ||
| Q2 25 | $61.4M | $70.8M | ||
| Q1 25 | — | $54.3M | ||
| Q4 24 | — | $-8.7M | ||
| Q3 24 | — | $36.1M | ||
| Q2 24 | — | $67.9M | ||
| Q1 24 | — | $51.5M |
| Q4 25 | — | — | ||
| Q3 25 | $-3.2M | $57.4M | ||
| Q2 25 | $-5.3M | $-3.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-2.0M | ||
| Q2 24 | — | $-11.3M | ||
| Q1 24 | — | $-4.2M |
| Q4 25 | — | -0.9% | ||
| Q3 25 | 66.3% | 23.6% | ||
| Q2 25 | 65.7% | 25.1% | ||
| Q1 25 | — | 22.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 24.1% | ||
| Q1 24 | — | 19.7% |
| Q4 25 | — | -18.4% | ||
| Q3 25 | -3.7% | -11.4% | ||
| Q2 25 | -7.1% | -7.0% | ||
| Q1 25 | — | -14.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -19.7% | ||
| Q2 24 | — | -17.9% | ||
| Q1 24 | — | -19.2% |
| Q4 25 | — | — | ||
| Q3 25 | -4.7% | 116.5% | ||
| Q2 25 | -8.7% | -5.3% | ||
| Q1 25 | — | -6.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -5.4% | ||
| Q2 24 | — | -16.7% | ||
| Q1 24 | — | -8.2% |
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $-0.06 | $0.70 | ||
| Q2 25 | $-0.24 | $-0.05 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | — | $-0.03 | ||
| Q2 24 | — | $-0.15 | ||
| Q1 24 | — | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.6M | $31.0M |
| Total DebtLower is stronger | $0 | — |
| Stockholders' EquityBook value | $217.3M | $279.1M |
| Total Assets | $287.5M | $325.5M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $31.0M | ||
| Q3 25 | $198.6M | $22.8M | ||
| Q2 25 | $223.1M | $58.8M | ||
| Q1 25 | — | $34.8M | ||
| Q4 24 | — | $18.4M | ||
| Q3 24 | — | $20.0M | ||
| Q2 24 | — | $26.3M | ||
| Q1 24 | — | $36.8M |
| Q4 25 | — | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $30.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $279.1M | ||
| Q3 25 | $217.3M | $283.0M | ||
| Q2 25 | $214.2M | $223.1M | ||
| Q1 25 | — | $219.7M | ||
| Q4 24 | — | $221.9M | ||
| Q3 24 | — | $233.5M | ||
| Q2 24 | — | $229.4M | ||
| Q1 24 | — | $236.6M |
| Q4 25 | — | $325.5M | ||
| Q3 25 | $287.5M | $335.1M | ||
| Q2 25 | $303.0M | $257.9M | ||
| Q1 25 | — | $250.6M | ||
| Q4 24 | — | $256.7M | ||
| Q3 24 | — | $282.9M | ||
| Q2 24 | — | $280.3M | ||
| Q1 24 | — | $282.8M |
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.14× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.1M | $-8.3M |
| Free Cash FlowOCF − Capex | $9.6M | $-10.2M |
| FCF MarginFCF / Revenue | 14.1% | -44.7% |
| Capex IntensityCapex / Revenue | 0.8% | 8.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-8.3M | ||
| Q3 25 | $10.1M | $-37.3M | ||
| Q2 25 | $-13.3M | $-3.1M | ||
| Q1 25 | — | $-246.0K | ||
| Q4 24 | — | $-1.8M | ||
| Q3 24 | — | $6.4M | ||
| Q2 24 | — | $8.4M | ||
| Q1 24 | — | $-15.6M |
| Q4 25 | — | $-10.2M | ||
| Q3 25 | $9.6M | $-40.1M | ||
| Q2 25 | $-13.8M | $-5.4M | ||
| Q1 25 | — | $-2.9M | ||
| Q4 24 | — | $-6.3M | ||
| Q3 24 | — | $-3.0M | ||
| Q2 24 | — | $-7.7M | ||
| Q1 24 | — | $-16.4M |
| Q4 25 | — | -44.7% | ||
| Q3 25 | 14.1% | -81.4% | ||
| Q2 25 | -22.6% | -7.6% | ||
| Q1 25 | — | -5.3% | ||
| Q4 24 | — | 72.7% | ||
| Q3 24 | — | -8.2% | ||
| Q2 24 | — | -11.4% | ||
| Q1 24 | — | -31.8% |
| Q4 25 | — | 8.1% | ||
| Q3 25 | 0.8% | 5.7% | ||
| Q2 25 | 1.0% | 3.2% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | — | -52.6% | ||
| Q3 24 | — | 25.8% | ||
| Q2 24 | — | 23.8% | ||
| Q1 24 | — | 1.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OMDA
| Services | $62.9M | 93% |
| Hardware | $5.1M | 7% |
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
